Conference Coverage
Conference Coverage
Approach can cure even high-risk FL, study suggests
The study showed that many patients transplanted in complete remission (CR) did not relapse and could be considered cured. Patients transplanted...
Conference Coverage
Antibody shows activity in relapsed/refractory NHL
“It is encouraging to see results in an NHL study that selects a different target than CD20,” said Kristie Blum, MD, of The Ohio State University...
Conference Coverage
Ofatumumab maintenance halves risk of progression in relapsed CLL
Key clinical point: Maintenance ofatumumab cuts the risk of progression in half among patients with relapsed CLL. Major finding: Progression-free...
Conference Coverage
VIDEO: Are chemo-free regimens possible for CLL?
Conference Coverage
VIDEO: ABT-199 alone and in combination shows promise against advanced CLL
Conference Coverage
ABT-199 rebounds in advanced CLL after tackling tumor lysis syndrome
Major finding: The overall response rate was 77% with ABT-199 monotherapy and 84% with the addition of rituximab in relapsed or refractory CLL....
Conference Coverage
ONO-4059 delivered hit to relapsed/refractory CLL
Key clinical point: ONO-4059 induced responses in most patients with relapsed/refractory CLL, including those with a 17p deletion. Major finding:...
Conference Coverage
Idelalisib efficacy remains rock steady in relapsed CLL
Major finding: Idelalisib and rituximab significantly increased progression-free survival (HR, 0.18; P less than .0001). Data source: A...
Conference Coverage
Ibrutinib holds CLL at bay in majority of patients at 30 months
Major finding: At 30 months of follow-up, overall survival with ibrutinib monotherapy was 96.6% among patients with newly diagnosed chronic...
Conference Coverage
Novel agent shows promising activity in heavily pretreated NHL
©ASCO/Rodney White CHICAGO—The novel, oral selective inhibitor of nuclear transport known as selinexor (KPT-330) can safely be given as...